In other biotech news, check out Endonovo Therapeutics, Inc. (OTCQB: ENDV), 22nd Century Group, Inc. (XXII), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), Emerald Health Therapeutics, Inc. (CVE: EMH) (OTCQX: EMHTF), and Lexington Biosciences, Inc.
Endonovo Therapeutics, Inc. (OTCQB: ENDV)
Market Cap: $14.195M, current share price: $.0465
Endonovo's FDA-Cleared and CE Marked non-invasive medical device, SofPulse(TM), delivers Electroceutical(TM) therapy to reduce pain and post-surgical swelling. ENDV's SofPulse(TM) also has CMS National Coverage (Medicare reimbursement) for the treatment of chronic wounds. SofPulse(TM) aims to reduce the dependency on narcotics following surgeries, such as breast augmentation surgery, by reducing the underlying cause of the pain itself: inflammation. Clinical trials on SofPulse(TM) have shown a 57% reduction in pain at one hour post breast augmentation surgery, a 300% reduction in pain at 5 hours post surgery, and a 2.2-fold reduction in narcotics use. Furthermore, ENDV is developing its Electroceutical(TM) therapy for the treatment of cerebrovascular and cardiovascular diseases, which have an underlying inflammatory component. With clinical data showing improvements in SAQ scores for angina severity and physical capacity in patients with end-stage ischemic heart disease and failed medical therapy and revascularization options ("no option" patients), Endonovo Therapeutics, Inc. (ENDV) is severely undervalued compared to its peers, such as Pulse Biosciences and Helius Medical Technologies, and is worth multiples of today's prices.
